Abdul‐Ghani MA et al. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care. 2009; 32(2):281–286.50 50. Peddinti G et al. 1‐hour post‐OGTT glucose improves the early prediction of type 2 diabetes by clinical and metabolic markers. J Clin Endocrinol Metab. 2019; 104(4):1131–1140.
51 51. Peddinti G et al. Early metabolic markers identify potential targets for the prevention of type 2 diabetes. Diabetologia. 2017; 60(9):1740–1750.
52 52. Priya M et al. 1‐hour venous plasma glucose and incident prediabetes and diabetes in Asian Indians. Diabetes Technol Ther. 2013; 15(6):497–502.
53 53. Wu S et al. Transition from pre‐diabetes to diabetes and predictors of risk in Mexican‐Americans. Diabetes Metab Syndr Obes. 2017; 10:491–503.
54 54. Abdul‐Ghani MA et al. What is the best predictor of future type 2 diabetes? Diabetes Care. 2007; 30(6):1544–1548.
55 55. Gabir MM et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care. 2000; 23(8):1113–1118.
56 56. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent‐onset diabetes in the Diabetes Prevention Program. Diabet Med. 2007; 24(2):137–144.
57 57. Colagiuri S et al. Glycemic thresholds for diabetes‐specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011; 34(1):145–150.
58 58. Tapp RJ et al. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia. Diabetes Res Clin Pract. 2006; 73(3):315–321.
59 59. Plantinga LC et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010; 5(4):673–682.
60 60. Metcalf PA et al. Microalbuminuria in a middle‐aged workforce. Effect of hyperglycemia and ethnicity. Diabetes Care. 1993; 16(11):1485–1493.
61 61. Echouffo‐Tcheugui JB et al. Association between prediabetes and risk of chronic kidney disease: a systematic review and meta‐analysis. Diabet Med. 2016; 33(12):1615–1624.
62 62. Dyck PJ et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993; 43(4):817–824.
63 63. Putz Z et al. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care. 2009; 32(1):181–183.
64 64. Grover SA et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006; 166(2):213–219.
65 65. Hoffman‐Snyder C et al. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol. 2006; 63(8):1075–1079.
66 66. Nathan DM et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30(3):753–759.
67 67. Barr EL et al. Risk of cardiovascular and all‐cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007; 116(2):151–157.
68 68. Huang Y et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta‐analysis. BMJ. 2016;355: i5953.
69 69. Stacey RB et al. Prediabetes and the association with unrecognized myocardial infarction in the multi‐ethnic study of atherosclerosis. Am Heart J. 2015; 170(5):923–928.
70 70. Brunner EJ et al. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care. 2006; 29(1):26–31.
71 71. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta‐analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215–2222.
72 72. Rao Kondapally Seshasai S et al. Diabetes mellitus, fasting glucose, and risk of cause‐specific death. N Engl J Med. 2011; 364(9):829–841.
73 73. Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002; 25(12):2165–2171.
74 74. Hamman RF et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006; 29(9):2102–2107.
75 75. Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3(11):866–875.
76 76. Ratner R et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005; 28(4):888–894.
77 77. Florez H et al. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med. 2012; 27(12):1594–1601.
78 78. Diabetes Prevention Program Research Group. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care. 2012; 35(4):723–730.
79 79. Pan XR et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20(4):537–544.
80 80. Gong Q et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30‐year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019; 7(6):452–461.
81 81. Madsen KS et al. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019; 12:CD008558.
82 82. le Roux CW et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet. 2017; 389(10077):1399–1409.
83 83. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367(4):319–328.
84 84. DeFronzo RA et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011; 364(12):1104–1115.
85 85. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368(9541):1096–1105.
86 86. Knowler WC et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005; 54(4):1150–1156.
87 87. Torgerson JS et al. XENical in the prevention of diabetes
